Clinical isolates of Aspergillus species remain fully susceptible to voriconazole in the post-voriconazole era

Antimicrob Agents Chemother. 2008 Sep;52(9):3444-6. doi: 10.1128/AAC.00629-08. Epub 2008 Jul 7.

Abstract

We studied the activity of voriconazole against 400 clinical strains of Aspergillus from the pre-voriconazole (1999 to 2002) and post-voriconazole (2003 to 2007) periods. Although the mean MICs of strains from the post-voriconazole period were slightly higher (0.39 versus 0.57 microg/ml; P < 0.001), all strains were susceptible to voriconazole and presented an MIC of <or=2 microg/ml.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antifungal Agents* / pharmacology
  • Antifungal Agents* / therapeutic use
  • Aspergillosis / drug therapy*
  • Aspergillosis / microbiology*
  • Aspergillus / classification
  • Aspergillus / drug effects*
  • Aspergillus / isolation & purification
  • Drug Resistance, Bacterial
  • Humans
  • Microbial Sensitivity Tests / standards
  • Pyrimidines* / pharmacology
  • Pyrimidines* / therapeutic use
  • Spain
  • Time Factors
  • Treatment Outcome
  • Triazoles* / pharmacology
  • Triazoles* / therapeutic use
  • Voriconazole

Substances

  • Antifungal Agents
  • Pyrimidines
  • Triazoles
  • Voriconazole